| Publications about 'therapy resistance' |
| Articles in journal or book chapters |
| Metastatic melanoma presents a formidable challenge in oncology due to its high invasiveness and resistance to current treatments. Central to its ability to metastasize is the Notch signaling pathway, which, when activated through direct cell-cell interactions, propels cells into a metastatic state through mechanisms akin to the epithelial-mesenchymal transition (EMT). While the upregulation of miR-222 has been identified as a critical step in this metastatic progression, the mechanism through which this upregulation persists in the absence of active Notch signaling remains unclear. Here we introduce a dynamical system model that integrates miR-222 gene regulation with histone feedback mechanisms. Through computational analysis, we delineate the non-linear decision boundaries that govern melanoma cell fate transitions, taking into account the dynamics of Notch signaling and the role of epigenetic modifications. Our approach highlights the critical interplay between Notch signaling pathways and epigenetic regulation in dictating the fate of melanoma cells. |
| There is growing recognition that phenotypic plasticity enables cancer cells to adapt to various environmental conditions. An example of this adaptability is the persistence of an initially sensitive population of cancer cells in the presence of therapeutic agents. Understanding the implications of this drug-induced resistance is essential for predicting transient and long-term tumor tumor dynamics subject to treatment. This paper introduces a mathematical model of this phenomenon of drug-induced resistance which provides excellent fits to time-resolved in vitro experimental data. From observational data of total numbers of cells, the model unravels the relative proportions of sensitive and resistance subpopulations, and quantifies their dynamics as a function of drug dose. The predictions are then validated using data on drug doses which were not used when fitting parameters. The model is then used, in conjunction with optimal control techniques, in order to discover dosing strategies that might lead to better outcomes as quantified by lower total cell volume. |
| Cancer therapies often fail when intolerable toxicity or drug-resistant cancer cells undermine otherwise effective treatment strategies. Over the past decade, adaptive therapy has emerged as a promising approach to postpone emergence of resistance by altering dose timing based on tumor burden thresholds. Despite encouraging results, these protocols often overlook the crucial role of toxicity-induced treatment breaks, which may permit tumor regrowth. Herein, we explore the following question: would toxicity feedback improve or hinder the efficacy of adaptive therapy? To address this question, we propose a mathematical framework for incorporating toxic feedback into treatment design. We find that the degree of competition between sensitive and resistant populations, along with the growth rate of resistant cells, critically modulates the impact of toxicity feedback on time to progression. Further, our model identifies circumstances where strategic treatment breaks, which may be based on either tumor size or toxicity, can mitigate overtreatment and extend time to progression, both at the baseline parameterization and across a heterogeneous virtual population. Taken together, these findings highlight the importance of integrating toxicity considerations into the design of adaptive therapy. |
This material is presented to ensure timely dissemination of scholarly and technical work. Copyright and all rights therein are retained by authors or by other copyright holders.
This document was translated from BibTEX by bibtex2html